Hepatitis C Virus Clinical Trial
Official title:
Associations of Hematologic Malignancies and Thyroid Cancer With HCV Infection Among US Military Veterans
This study will investigate the possible relationship between infection with hepatitis C
virus (HCV) and the development of certain hematologic cancers (Non-Hodgkin's lymphoma,
Hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma) and thyroid cancer. HCV
causes chronic hepatitis, cirrhosis, and liver cancer. It is transmitted primarily through
injection drug use and transfusion of infected blood. Studies have shown that HCV may also be
linked to hematologic cancers and thyroid cancer.
This retrospective study will examine medical records from veterans with and without HCV
infection who previously received treatment in the Veterans Administration medical system.
Data collected on each subject will include the subject's race, sex, age and era of military
service, presence of liver disease or thyroiditis at their baseline clinic visit, number of
inpatient visits in the past 5 years and outpatient visits in the past year, and the presence
of various specified cancers. The prevalence of cancer and other conditions among
HCV-infected subjects and non-HCV infected subjects at baseline and the subsequent
development of the cancers of interest in these two groups will be compared and analyzed for
a possible causal relationship.
Hepatitis C virus (HCV) may be a cause of hematologic malignancies and thyroid cancer. HCV
infection is common among U.S. military veterans receiving care in the Veterans
Administration healthcare system. The investigators propose a retrospective cohort study
using VA administrative databases. A cohort of approximately 147,000 HCV-infected veterans
has been identified for the period 1997-2004. Likewise, a cohort of approximately 573,000
HCV-uninfected veterans has been identified for the same period. These subjects are being
evaluated for the diagnosis of hematologic malignancies, thyroid cancer, and related medical
conditions as recorded in VA databases. The comparison of the prevalence and incidence of
these cancers in the two cohorts will provide a test of the hypothesis that HCV infection can
cause these cancers.
The investigators will also evaluate the association between HCV infection and several other
medical conditions, which might be related to HCV infection, specifically: immune
thrombocytopenic purpura, autoimmune hemolytic anemia, cholangiocarcinoma, cholangitis, and
pancreatic cancer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02907996 -
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
|
||
| Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
| Not yet recruiting |
NCT02893046 -
HCV Care Pathway in Ile-de-France
|
N/A | |
| Completed |
NCT01396005 -
A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
|
Phase 1 | |
| Completed |
NCT01428063 -
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
|
Phase 2 | |
| Completed |
NCT01195181 -
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
|
Phase 4 | |
| Completed |
NCT00219999 -
Hepatitis C Virus and the Humoral Immune System
|
N/A | |
| Completed |
NCT02243293 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
|
Phase 2/Phase 3 | |
| Completed |
NCT02265237 -
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
|
Phase 3 | |
| Not yet recruiting |
NCT06104046 -
Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis
|
||
| Completed |
NCT02604017 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
|
Phase 3 | |
| Withdrawn |
NCT00947245 -
Japanese Bridging Study Conducted in the United States
|
Phase 1 | |
| Completed |
NCT01713283 -
Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
|
Phase 2 | |
| Completed |
NCT01458535 -
A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
|
Phase 2 | |
| Completed |
NCT01479881 -
A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus
|
Phase 1 | |
| Completed |
NCT01193361 -
Ph IIA Study (SOC +/- NS5B)
|
Phase 2 | |
| Completed |
NCT01241773 -
TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir
|
Phase 1 | |
| Completed |
NCT01006031 -
Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
|
Phase 2/Phase 3 | |
| Completed |
NCT00819026 -
Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors
|
N/A | |
| Completed |
NCT00382798 -
Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin
|
Phase 1/Phase 2 |